GW Pharmaceuticals plc was a big mover last session, as the company saw its shares rise over 6% on the day. The upside came as the company announced positive Phase 3 pivotal trial results for Epidiolex (cannabidiol) in the treatment of Lennox-Gastaut syndrome. This led to solid volume too with far more shares changing hands than in a normal session. This stock, trading in a volatile price range of $83.31 to $94.19 in the past one-month time frame, showed a pick-up yesterday at $88.49.

The company has seen no estimate revisions over the past 7 days, while the Zacks Consensus Estimate remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

GW Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

GW PHARMA-ADR Price

GW PHARMA-ADR Price | GW PHARMA-ADR Quote

A better-ranked stock in the same industry is Boston Scientific Corporation (BSX Quick QuoteBSX - Free Report) , which carries a Zacks Rank #2 (Buy).

Is GWPH going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>